One case of myositis with myasthenia gravis caused by camrelizumab in esophageal cancer
10.3781/j.issn.1000-7431.2023.2207-0594
- VernacularTitle:卡瑞利珠单抗致食管癌患者多发性肌炎伴重症肌无力1例
- Author:
Yingnan WANG
1
;
Yao FAN
;
Fangyi SUN
;
Ying HAN
;
Shengmei GE
;
Fengbin ZHANG
;
Ruixing ZHANG
Author Information
1. 河北医科大学第四医院消化内科,河北 石家庄 050011
- Keywords:
Immune checkpoint inhibitors;
Myositis;
Myasthenia gravis;
Esophageal cancer
- From:
Tumor
2023;43(2):157-160
- CountryChina
- Language:Chinese
-
Abstract:
Although immune checkpoint inhibitors(ICIs)are widely used in cancer therapy,showing great advantages and development potential,it is accompanied by a series of immune-related adverse reactions,of which myositis is a potentially fatal adverse event,which has attracted great attention.Herein,we reported a case of advanced esophageal cancer with myositis after treatment with camrelizumab,which was characterized by myasthenia gravis(MG)with myasthenic crisis,and recovered after active rescue by multidisciplinary cooperation.
